• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
SUN Zhijie,WANG Xiaoshan,LI Yamin.Exploration on the research progress of traditional Chinese medicine in the treatment of cerebral infarction based on TXNIP/NLRP3/caspase-1 signaling pathways[J].Journal Of Pharmaceutical Research,2026,45(9):1052-1057,1076[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 230times   Download 190次 QR Code for this article
Scan with your phone!
基于TXNIP/NLRP3/caspase-1信号通路探讨中药治疗脑梗死研究进展
孙志杰1,王晓姗2,李亚敏1
Font:Larger+|Default|Smaller-
(1.赤峰大学附属医院中药房,内蒙古 赤峰 024000;2.赤峰大学附属医院中医妇科,内蒙古 赤峰 024000)
摘要:
脑梗死又称为缺血性脑卒中(IS),属于临床上常见的重大神经系统性疾病,具有治疗难度大、致残、致死率高的特点。IS的病理、生理过程涉及氧化应激反应、炎症反应及细胞焦亡等多重机制,可引起局部脑组织血供障碍,导致脑细胞缺血、缺氧性死亡,进而损伤患者神经功能。硫氧还蛋白互作蛋白/NOD样受体家族蛋白3/半胱氨酸天冬氨酸蛋白酶1(TXNIP/NLRP3/caspase-1)信号通路是介导细胞焦亡和炎症反应的重要信号通路之一,在IS发生、发展与再灌注损伤中发挥关键作用。近年来,随着中医诊疗技术的发展,中药治疗在IS临床治疗领域展现出良好的前景,能够通过调控TXNIP/NLRP3/caspase-1信号通路缓解脑组织损伤、修复神经损伤。本文将基于TXNIP/NLRP3/caspase-1信号通路探讨中药治疗IS研究进展,为中药治疗IS的临床前研究和未来临床转化提供理论依据。
关键词:  脑梗死  中药治疗  硫氧还蛋白互作蛋白/NOD样受体家族蛋白3/半胱氨酸天冬氨酸蛋白酶1信号通路  炎症反应  细胞焦亡
DOI:10.13506/j.cnki.jpr.2026.09.014
基金项目:内蒙古自治区自然科学基金项目(No.2025MS08065)
Received Date:April 14, 2026   Revision Date:July 17, 2026   Publication Date:September 30, 2026
Exploration on the research progress of traditional Chinese medicine in the treatment of cerebral infarction based on TXNIP/NLRP3/caspase-1 signaling pathways
SUN Zhijie1,WANG Xiaoshan2,LI Yamin1
(1.Pharmacy of Traditional Chinese Medicine,Chifeng University Affiliated Hospital, Chifeng 024000,China;2.Department of TCM Gynecology,Chifeng University Affiliated Hospital, Chifeng 024000,China)
Abstract:
Cerebral infarction, also known as ischemic stroke (IS), is a common major neurological disease in clinical practice, which is characterized by difficult treatment, high disability and mortality. The pathological and physiological process of IS involves multiple mechanisms such as oxidative stress response, inflammatory response and pyroptosis, which can cause blood supply disorder in local brain tissue, ischemia/hypoxia death of brain cells, and thus damage nerve function of patients. The thioredoxin interacting protein/NOD-like receptor family protein 3/cysteine aspartase-1 (TXNIP/NLRP3/caspase-1) signaling pathways are important pathways mediating pyroptosis and inflammatory response, which play key roles in IS occurrence, development and reperfusion injury. In recent years, with the development of TCM diagnosis and treatment technology, TCM has shown a good prospect in the clinical treatment of IS, which can alleviate brain tissue injury and repair nerve injury by regulating TXNIP/NLRP3/caspase-1 signaling pathways. This article will discuss the research progress of traditional Chinese medicine in the treatment of IS based on TXNIP/NLRP3/caspase-1 signaling pathways, which provides theoretical basis for pre-clinical study and Future clinical translation of traditional Chinese medicine in the treatment of IS.
Key words:  Cerebral infarction  Traditional Chinese medicine treatment  Thioredoxin interacting protein/NOD-like receptor family protein 3/cysteine aspartase-1 signaling pathway  Inflammatory response  Pyroptosis
Today's Visits:447    Total Visits:2383131
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.